This is a long term investment. It takes years to develop and release new drugs. The future is bright for this company but it won't happen overnight. If you're a trader looking for a quick flip this is probably not the right stock for you. It's a bit like watching paint dry. However, if you're an investor, it's a good bet that by the end of the year, as we draw closer to clinical trials, this stock will be trading at a higher pps.
The thing that can change this picture and speed things up is if InMed finds a way to monetize their bioinformatics and/or biosynthesis processes, or they contract with a bigger company for a JV or some type of acquisition.
News 
Market Data 
Discover 
